| Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors (NCT00954148) | Dallas VA Medical Center | 2009-09-01 |
| Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors (NCT00887757) | AbbVie | 2009-09-01 |
| Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology (NCT02140736) | Hospira, now a wholly owned subsidiary of Pfizer | 2009-09-01 |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors (NCT00858377) | Amgen | 2009-08-10 |
| A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382) | Astellas Pharma Inc | 2009-08-05 |
| Study of KRN951 in Patients With Solid Tumors (NCT00970411) | Kyowa Kirin Co., Ltd. | 2009-08-01 |
| Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma (NCT00978523) | Arno Therapeutics | 2009-08-01 |
| Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 (NCT00973076) | AstraZeneca | 2009-08-01 |
| Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor (NCT01299415) | Novartis Pharmaceuticals | 2009-08-01 |
| Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing (NCT00909207) | M.D. Anderson Cancer Center | 2009-07-01 |
| Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors (NCT00949559) | Esperance Pharmaceuticals Inc | 2009-07-01 |
| Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine (NCT00937664) | AstraZeneca | 2009-07-01 |
| Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors (NCT00942799) | Genzyme, a Sanofi Company | 2009-07-01 |
| Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors (NCT00891605) | AbbVie | 2009-07-01 |
| Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor (NCT01362985) | Genzyme, a Sanofi Company | 2009-07-01 |
| Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours (NCT00918320) | Gustave Roussy, Cancer Campus, Grand Paris | 2009-06-01 |
| Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors (NCT00925275) | Cellectar, Inc | 2009-06-01 |
| Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection (NCT00918281) | GE Healthcare | 2009-06-01 |
| Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer (NCT00909025) | Ganymed Pharmaceuticals GmbH | 2009-05-31 |
| Erlotinib and Temsirolimus for Solid Tumors (NCT00770263) | Washington University School of Medicine | 2009-05-01 |
| A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (NCT00884312) | Amgen | 2009-04-09 |
| Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (NCT00878111) | AGC Biologics S.p.A. | 2009-04-01 |
| A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers (NCT00900497) | Dipnarine Maharaj | 2009-04-01 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer (NCT00807859) | Amgen | 2009-03-09 |
| Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors (NCT00839631) | Dendreon | 2009-03-01 |
| Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (NCT00888043) | Herbert Hurwitz, MD | 2009-03-01 |
| Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement (NCT00882180) | Alnylam Pharmaceuticals | 2009-03-01 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (NCT00819169) | NantCell, Inc. | 2009-01-16 |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours (NCT00819221) | AstraZeneca | 2009-01-05 |
| A Study of QBI-139 in Subjects With Advanced Solid Tumors (NCT00818831) | Quintessence Biosciences, Inc. | 2009-01-01 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (NCT00770536) | Amgen | 2009-01-01 |
| Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer (NCT00773929) | Millennium Pharmaceuticals, Inc. | 2009-01-01 |
| Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors (NCT01125891) | Traws Pharma, Inc. | 2009-01-01 |
| Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors (NCT01214668) | Eli Lilly and Company | 2009-01-01 |
| QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (NCT00791154) | NantCell, Inc. | 2008-12-02 |
| Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors (NCT00765973) | Spectrum Pharmaceuticals, Inc | 2008-11-10 |
| Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy. (NCT00805636) | Aposense Ltd. | 2008-11-01 |
| Phase I Comparative Bioavailability Study (NCT00777582) | AstraZeneca | 2008-10-27 |
| A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour (NCT00778128) | Clavis Pharma | 2008-10-01 |
| A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors (NCT00869388) | Washington University School of Medicine | 2008-10-01 |
| Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors (NCT00776867) | Memorial Sloan Kettering Cancer Center | 2008-10-01 |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) (NCT00749502) | Tesaro, Inc. | 2008-09-01 |
| Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors (NCT00754104) | Abbott | 2008-09-01 |
| Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors (NCT00582816) | University of Wisconsin, Madison | 2008-08-01 |
| A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors (NCT00744562) | OncoMed Pharmaceuticals, Inc. | 2008-08-01 |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (NCT00741403) | Cornerstone Pharmaceuticals | 2008-08-01 |
| Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 (NCT00733031) | AstraZeneca | 2008-08-01 |
| A Study of Tor Kinase Inhibitor in Advanced Tumors (NCT00731263) | AstraZeneca | 2008-07-01 |
| Hepatic Arterial Infusion (HAI) of Abraxane (NCT00732836) | M.D. Anderson Cancer Center | 2008-06-01 |
| Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours (NCT00702494) | BioInvent International AB | 2008-06-01 |
| A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors (NCT00674947) | Biogen | 2008-06-01 |
| Cardiac Safety Assessment Study of Picoplatin in Solid Tumors (NCT00710697) | Poniard Pharmaceuticals | 2008-06-01 |
| Phase I Study of TAS-106 in Combo With Carboplatin (NCT00752011) | M.D. Anderson Cancer Center | 2008-06-01 |
| Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma (NCT00847366) | AEterna Zentaris | 2008-05-01 |
| Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) (NCT00700336) | CanBas Co. Ltd. | 2008-05-01 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors (NCT00569036) | Bristol-Myers Squibb | 2008-04-01 |
| A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer (NCT01062620) | Axelar AB | 2008-04-01 |
| Panitumumab in Children With Solid Tumors (NCT00658658) | Amgen | 2008-03-01 |
| Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (NCT00635596) | Amgen Research (Munich) GmbH | 2008-03-01 |
| 18F ML-10 for Early Detection of Response of Brain Metastases to WBRT (NCT00791063) | Aposense Ltd. | 2008-03-01 |
| Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib (NCT00667147) | University of Southern California | 2008-03-01 |
| Spirituality/Religiosity in Patients and Caregivers (NCT00634257) | M.D. Anderson Cancer Center | 2008-02-22 |
| Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain (NCT00634010) | M.D. Anderson Cancer Center | 2008-02-01 |
| A Phase I Trial of Bortezomib and Sunitinib (NCT00720148) | Emory University | 2008-02-01 |
| Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors (NCT01151384) | INSYS Therapeutics Inc | 2008-02-01 |
| A Phase 1 Study in Patients With Solid Tumors (NCT01215916) | Eli Lilly and Company | 2008-02-01 |
| Function and Balance for Inpatient Rehabilitation (NCT00601133) | M.D. Anderson Cancer Center | 2008-01-01 |
| A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) (NCT00704054) | Merck Sharp & Dohme LLC | 2008-01-01 |
| Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung (NCT00832780) | New Mexico Cancer Research Alliance | 2008-01-01 |
| Trial of MSC1936369B in Subjects With Solid Tumors (NCT00982865) | Merck KGaA, Darmstadt, Germany | 2007-12-31 |
| ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies (NCT00635284) | Celgene | 2007-12-01 |
| LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors (NCT00556088) | SCRI Development Innovations, LLC | 2007-12-01 |
| Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors (NCT00606814) | Infinity Pharmaceuticals, Inc. | 2007-12-01 |
| Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas (NCT00572637) | Ethical Oncology Science | 2007-11-01 |
| Evaluation of KX2-391 in Patients With Advanced Malignancies (NCT00658970) | Athenex, Inc. | 2007-11-01 |
| LBH589 and Gemcitabine in the Treatment of Solid Tumors (NCT00550199) | SCRI Development Innovations, LLC | 2007-11-01 |
| MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors (NCT00591682) | Metastatix, Inc. | 2007-11-01 |
| BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (NCT00586443) | Herbert Hurwitz, MD | 2007-11-01 |
| Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors (NCT00687934) | Synta Pharmaceuticals Corp. | 2007-10-01 |
| Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers (NCT00583063) | University of Chicago | 2007-10-01 |
| A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors (NCT00390936) | Bristol-Myers Squibb | 2007-10-01 |
| Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors (NCT00688116) | Synta Pharmaceuticals Corp. | 2007-10-01 |
| Trial of PBI-05204 in Advanced Cancer Patients (NCT00554268) | M.D. Anderson Cancer Center | 2007-10-01 |
| Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (NCT00531284) | Amgen | 2007-09-01 |
| L19TNFα in Patients With Advanced Solid Tumors (NCT01253837) | Philogen S.p.A. | 2007-09-01 |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas (NCT00553189) | National Cancer Institute (NCI) | 2007-08-09 |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer (NCT00529022) | M.D. Anderson Cancer Center | 2007-08-01 |
| Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor (NCT00483093) | AGC Biologics S.p.A. | 2007-07-01 |
| Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients (NCT00585221) | University of Utah | 2007-07-01 |
| Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension) (NCT00442741) | Novartis Pharmaceuticals | 2007-07-01 |
| Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study (NCT00487331) | M.D. Anderson Cancer Center | 2007-06-01 |
| A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors (NCT00560716) | Cyclacel Pharmaceuticals, Inc. | 2007-06-01 |
| Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor (NCT00495872) | M.D. Anderson Cancer Center | 2007-06-01 |
| Phase I Study in Advanced Solid Tumors (NCT00591292) | Alaunos Therapeutics | 2007-06-01 |
| ST1968 Intravenous (Weekly) in Solid Tumors (NCT01748019) | sigma-tau i.f.r. S.p.A. | 2007-06-01 |
| Study of Capecitabine In Patients With Solid Tumors (NCT00697502) | National University Hospital, Singapore | 2007-05-01 |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies (NCT00894894) | Astex Pharmaceuticals, Inc. | 2007-05-01 |
| Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors (NCT00636545) | Genta Incorporated | 2007-05-01 |
| Study of XL418 in Adults With Solid Tumors (NCT00460278) | Exelixis | 2007-04-01 |
| A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine (NCT00741234) | S*BIO | 2007-04-01 |